Black Diamond Therapeutics, Inc.

BDTX · United States

Share price · BDTX

$1.43-0.63 (-30.58%) 3M

close as of 2026-11-18 · 24h delayed · vol 603K (0.7x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when BDTX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 10 Nov 2026-14.2%
  2. 26 Oct 2026-10.1%
  3. 23 Oct 2026-9.6%
  4. 20 Oct 2026+14.4%
  5. 24 Jun 2026+15.5%
  6. 22 May 2026-35.8%
  7. 20 May 2026+20.0%
  8. 19 May 2026+16.3%
  9. 8 May 2026+9.9%
  10. 15 Apr 2026+7.9%

    Nothing announced by BDTX that day or the session before.

Share of unusual movement by asset

For each asset, the share of BDTX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Silevertinib
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—10%
Other company news (earnings, financing, releases naming no asset)—14%
Sessions with no dated event—76%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 1/2
EGFRSmall molecule
Non-Small Cell Lung CancerGlioblastoma
Non-Small Cell Lung Cancer with EGFR Mutations, Recurrent Glioblastoma with EGFR Alterations

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (2)
March 2028 (1)
SilevertinibPhase 1/2Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer …
Est. primary completion 2028-03 · NCT05256290 · CT.gov ↗
What to watch
November 2028 (1)
SilevertinibPhase 2Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM), Glioma, Central Nervous System Diseases, Brain Cancer
Est. primary completion 2028-11 · NCT07326566 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$0$7.0M$16M+ $87M short-term inv.$10M-$8.3M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0$7.4M$20M+ $91M short-term inv.$9.9M-$8.0M operating cash flowreport ↗
2026-Q1$0$7.0M$31M+ $88M short-term inv.$9.0M-$10M operating cash flowreport ↗
2025-Q3$0$7.4M$32M+ $105M short-term inv.$8.5M-$7.8M operating cash flowreport ↗
2025-Q2$0$9.3M$31M+ $113M short-term inv.$11M-$9.2M operating cash flowreport ↗
2025-Q1$70M$11M$99M+ $54M short-term inv.—$53M operating cash flowreport ↗
2024-Q3$0$13M$24M+ $89M short-term inv.$16M-$11M operating cash flowreport ↗
2024-Q2$0$13M$34M+ $90M short-term inv.$20M-$15M operating cash flowreport ↗
2024-Q1$0$14M$26M+ $90M short-term inv.$18M-$21M operating cash flowreport ↗
2023-Q3—$16M$59M+ $86M short-term inv.$23M-$18M operating cash flowreport ↗
2023-Q2—$13M$43M+ $48M short-term inv.$19M-$14M operating cash flowreport ↗
2023-Q1—$15M$40M+ $64M short-term inv.$21M-$20M operating cash flowreport ↗
2022-Q3—$16M$55M+ $90M short-term inv.$22M-$16M operating cash flowreport ↗
2022-Q2—$16M$57M+ $105M short-term inv.$23M-$18M operating cash flowreport ↗
2022-Q1—$18M$55M+ $126M short-term inv.$26M-$29M operating cash flowreport ↗
2021-Q3—$28M$48M+ $188M short-term inv.$35M-$26M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$70M$34M$22M+ $108M short-term inv.—$30M operating cash flowreport ↗

For fiscal year 2025, Black Diamond Therapeutics reported revenue of $70M, compared with $0M in the prior year, reflecting the upfront payment from the Servier license. R&D expense was $33.56M, down 34.6% YoY, and the company ended the year with $21.82M in cash and equivalents and net income of $22.37M.

The company’s lead candidate, silevertinib, is in a Phase 2 trial in EGFR-mutant non-small cell lung cancer; initial frontline data announced in December 2025 showed a 60% objective response rate, 86% CNS response rate, and 91% disease control rate at the November 3, 2025 cutoff, with updated duration of response and progression-free survival results planned for the second quarter of 2026. A randomized Phase 2 trial in newly diagnosed EGFR-altered glioblastoma is expected to begin in the second quarter of 2026. BDTX-4933 was outlicensed to Servier in the first quarter of 2025, with eligibility for up to $710M in milestone payments and tiered royalties, and the company continues to evaluate partnerships for silevertinib and strategic alternatives for BDTX-4876.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0$51M$37M+ $62M short-term inv.$17M-$62M operating cash flowreport ↗
2023-FY—$59M$57M+ $75M short-term inv.$21M-$67M operating cash flowreport ↗
2022-FY—$64M$35M+ $88M short-term inv.$23M-$85M operating cash flowreport ↗
2021-FY—$97M$67M+ $144M short-term inv.$31M-$100M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-18Behbahani Ali · directorAward / grant7,707$1.93$15KForm 4
2026-09-18Raman Prakash · directorAward / grant6,801$1.93$13KForm 4
2026-06-26Campbell Shannon · directorAward / grant (derivative)40,000——Form 4
2026-06-26Dhingra Kapil · directorAward / grant (derivative)40,000——Form 4
2026-06-26Raman Prakash · directorAward / grant (derivative)40,000——Form 4
2026-06-26Menzel Garry E · directorAward / grant (derivative)40,000——Form 4
2026-06-26Kulkarni Samarth · directorAward / grant (derivative)40,000——Form 4
2026-06-26Behbahani Ali · directorAward / grant (derivative)40,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 103 reporting institutions held 38.5M shares ($54.2M).

#InstitutionSharesValue
1NEA Management Company, LLC4,448,757$9.5M
2VANGUARD CAPITAL MANAGEMENT LLC1,850,468$3.9M
3RENAISSANCE TECHNOLOGIES LLC1,643,747$3.5M
4DIMENSIONAL FUND ADVISORS LP1,301,664$2.8M
5BlackRock, Inc.1,106,840$2.4M
6Connor, Clark & Lunn Investment Management Ltd.1,058,397$2.3M
7MACKENZIE FINANCIAL CORP844,835$1.8M
8MARSHALL WACE, LLP836,266$1.8M
9ARROWSTREET CAPITAL, LIMITED PARTNERSHIP834,570$1.8M
10BRIDGEWAY CAPITAL MANAGEMENT, LLC723,477$1.5M
11GOLDMAN SACHS GROUP INC684,418$1.5M
12FMR LLC623,827$1.3M
13UBS Group AG564,838$1.2M
14Man Group plc559,700$1.2M
15WINTON GROUP Ltd538,259$1.1M